Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients
October 12, 2022 at 10:07 AM EDT
Moderna's vaccine is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form skin cancer.
